TD Asset Management
MLTX icon

TD Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

TD Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Sell
128,274
-14,432
-10% -$262K ﹤0.01% 927
2026
Q1 		$2.66M Buy
142,706
+15,962
+13% +$264K ﹤0.01% 908
2025
Q4 		$1.67M Buy
126,744
+20,134
+19% +$238K ﹤0.01% 1021
2025
Q3 		$764K Sell
106,610
-79,542
-43% -$4.15M ﹤0.01% 1128
2025
Q2 		$8.79M Sell
186,152
-30,752
-14% -$1.25M 0.01% 665
2025
Q1 		$8.47M Sell
216,904
-44,730
-17% -$1.93M 0.01% 677
2024
Q4 		$14.2M Buy
261,634
+45,800
+21% +$2.34M 0.01% 579
2024
Q3 		$10.7M Buy
215,834
+6,600
+3% +$309K 0.01% 631
2024
Q2 		$9.2M Buy
209,234
+5,140
+3% +$218K 0.01% 632
2024
Q1 		$10.3M Sell
204,094
-5,048
-2% -$274K 0.01% 621
2023
Q4 		$12.6M Buy
209,142
+8,752
+4% +$451K 0.01% 581
2023
Q3 		$11.4M Buy
200,390
+100,750
+101% +$5.56M 0.01% 561
2023
Q2 		$5.08M Buy
99,640
+32,328
+48% +$870K 0.01% 738
2023
Q1 		$1.44M Hold
67,312
– – ﹤0.01% 1065
2022
Q4 		$707K Hold
67,312
– – ﹤0.01% 1213
2022
Q3 		$538K Buy
67,312
+38,346
+132% +$271K ﹤0.01% 1286
2022
Q2 		$152K Buy
+28,966
New +$182K ﹤0.01% 1397
2022
Q1 		– Sell
-44,766
Closed -$443K – 1500
2021
Q4 		$443K Hold
44,766
– – ﹤0.01% 1398
2021
Q3 		$442K Hold
44,766
– – ﹤0.01% 1409
2021
Q2 		$444K Hold
44,766
– – ﹤0.01% 1402
2021
Q1 		$458K Hold
44,766
– – ﹤0.01% 1414
2020
Q4 		$485K Buy
+44,766
New +$475K ﹤0.01% 1339

Other funds holding MLTX

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AG
Algert Global San Francisco, California $8.43B AUM 80.94% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

TD Asset Management's MLTX Position: Q2 2026 in Review

TD Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 10% in Q2 2026, selling an estimated $262K and leaving 128,274 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #927.

TD Asset Management first reported a position in MLTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $14.2M in Q4 2024. 91 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • TD Asset Management held 128,274 shares of MoonLake Immunotherapeutics worth $2.5M as of Q2 2026.
  • TD Asset Management sold 14,432 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $262K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #927 holding.
  • TD Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 22 quarters since.
  • TD Asset Management's MoonLake Immunotherapeutics position peaked at $14.2M in Q4 2024.
  • 91 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.